Future studies are needed to explore in detail how ZNF692 interacts with these signaling pathways and other potentially relevant factors, and how these interactions contribute to prostate cancer aggressiveness, migration, treatment resistance, and recurrence. This evidence concerns the gene ZNF692 and Familial prostate cancer.